Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05360966 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)
A Phase 3 study of Dry Eye Disease, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 467
- Enrollment target
- 20
- Study locations
NCT05360966 is a Phase 3 study of Dry Eye Disease that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 467 participants, above the 241-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (94% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT05360966, a Phase 3 study of Dry Eye Disease, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 467 participants
- Enrollment target
- 20
- Study locations
Study Summary
This will be a Phase 3, multicenter, vehicle-controlled, double-masked, randomized study conducted at approximately 20 sites in the United States. All subjects enrolled will have dry eye disease (DED). The study will consist of Screening (Day -14) and Baseline (Day 1) visits as well as visits at Day 7, Day 14, Day 28, and Day 90 (Study Exit) for an individual duration of participation of approximately 15 weeks.
Conditions Studied
Interventions
- DRUG 0.003% AR-15512 ophthalmic solution
- DRUG AR-15512 vehicle ophthalmic solution
Study Locations (20)
California
- Reeve Woods Eye Center - Chico
- NVision Clinical Research, LLC - Fullerton
- Eye Research Foundation - Newport Beach
- Shultz Vision - Northridge
- NVision Clinical Research, LLC - Torrance
Massachusetts
- Andover Eye Associates - Andover
- Boston Vision - Milford
- Andover Eye Associates - Raynham - Raynham
North Carolina
- Oculus Research - Garner
- Wilmington Eye - Leland
- Pure Ophthalmic Research - Mint Hill
Illinois
- Jackson Eye - Lake Villa
- Wyse Eyecare - Northbrook
Florida
- Argus Research Center - Cape Coral
Indiana
- Pankratz Eye Institute - Columbus
Nevada
- AdvanceMed Clinical Research - Las Vegas
New York
- NVision Clinical Research, LLC - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 467 participants |
| Start Date | 2022-07-18 |
| Est. Completion | 2023-10-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05360966
The ClinicalTrials.gov registry entry for NCT05360966 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 467 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 241-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (94% higher). The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which 0.003% AR-15512 ophthalmic solution is the first listed.
NCT05360966 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05360966 about?
NCT05360966 is a clinical study titled "Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)". This will be a Phase 3, multicenter, vehicle-controlled, double-masked, randomized study conducted at approximately 20 sites in the United States. All subjects enrolled will have dry eye disease (DED). The study will consist of Screening (Day -14) and Baseline (Day 1) visits as well as visits at Day...
What is the current status of trial NCT05360966?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 467 participants. The study started on 2022-07-18. Estimated completion is 2023-10-17.
What conditions does trial NCT05360966 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT05360966?
The interventions under investigation include: 0.003% AR-15512 ophthalmic solution (DRUG), AR-15512 vehicle ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT05360966?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05360966 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
RECRUITING · Phase 3
-
A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
COMPLETED · Phase 3
-
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
COMPLETED · Phase 3
-
A Study Designed to Evaluate Tear Production
COMPLETED · Phase 3
-
ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.